KNSA Kiniksa Corp: Net earnings per share for the last 12 months

Kiniksa Pharmaceuticals (KNSA) generates revenue from the therapy of rare inflammatory diseases, leveraging patent protection and lifelong demand. However, trade barriers and logistical disruptions complicate the expansion of its drugs. Stable sales maintain a loyal staff of scientists. The 12-month YoY EPS trend demonstrates profit dynamics, where the 192.50 level captures the latest values.
KNSA (Kiniksa Corp): analytical breakdowns and indicator data

This indicator captures the dynamics of net income per share over a rolling year, allowing for an assessment of the business's earnings scaling rates relative to previous periods. Analyzing the history of EPS YoY (TTM) percentage changes helps determine asset overvaluation, which is critical for Kiniksa Pharmaceuticals (KNSA) during the expansion of ARCALYST therapeutic indications and the development of its R&D pipeline targeting rare inflammatory diseases.